

NOTE: This order is nonprecedential.

**United States Court of Appeals
for the Federal Circuit**

NOVARTIS PHARMACEUTICALS CORPORATION,
Plaintiff-Appellee

v.

**ACCORD HEALTHCARE, INC., AUROBINDO
PHARMA LTD., AUROBINDO PHARMA USA, INC.,
DR. REDDY'S LABORATORIES, INC., DR. REDDY'S
LABORATORIES, LTD., EMCURE
PHARMACEUTICALS LTD., HERITAGE
PHARMACEUTICALS INC., GLENMARK
PHARMACEUTICALS INC., USA, GLENMARK
PHARMACEUTICALS LIMITED, HETERO USA,
INC., HETERO LABS LIMITED UNIT-V, HETERO
LABS LIMITED, MYLAN PHARMACEUTICALS,
INC., PRINSTON PHARMACEUTICAL INC.,
STRIDES GLOBAL PHARMA PRIVATE LIMITED,
STRIDES PHARMA, INC., TORRENT PHARMA
INC., TORRENT PHARMACEUTICALS LTD.,
ZYDUS PHARMACEUTICALS (USA) INC., CADILA
HEALTHCARE LTD., APOTEX INC., APOTEX
CORP., SUN PHARMACEUTICAL INDUSTRIES,
LTD., SUN PHARMACEUTICAL INDUSTRIES INC.,
SUN PHARMA GLOBAL FZE,**
Defendants

HEC PHARM CO., LTD., HEC PHARM USA INC.,
Defendants-Appellants

2 NOVARTIS PHARMACEUTICALS v. ACCORD HEALTHCARE INC.

2021-1070

Appeal from the United States District Court for the District of Delaware in No. 1:18-cv-01043-KAJ, Circuit Judge Kent A. Jordan.

ON PETITION FOR REHEARING EN BANC

Before MOORE, *Chief Judge*, LINN and HUGHES, *Circuit Judges*.

PER CURIAM.

ORDER

HEC Pharm Co., Ltd. and HEC Pharm USA Inc. filed a combined petition for panel rehearing and rehearing en banc. A response to the petition was invited by the court and filed by Novartis Pharmaceuticals Corporation. The petition for panel rehearing was referred to the merits panel and the petition was granted.¹

IT IS ORDERED THAT:

The petition for rehearing en banc is denied as moot.

FOR THE COURT

June 21, 2022

Date

/s/ Peter R. Marksteiner

Peter R. Marksteiner

Clerk of Court

¹ See accompanying opinion issued June 21, 2022.